» Articles » PMID: 29759295

Effect of Acute Kidney Injury After Percutaneous Mitral Valve Repair on Outcome

Overview
Journal Am J Cardiol
Date 2018 May 16
PMID 29759295
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Limited data exist on the occurrence of acute kidney injury (AKI) associated with percutaneous mitral valve repair (PMVR). The objectives of the present study were (1) to assess the prevalence of AKI after MitraClip (Abbott Vascular, Santa Clara, California) implantation, (2) to analyze the predictive factors of AKI, and (3) to evaluate the prognostic value of AKI after PMVR with a view to optimizing the management of high-risk patients. A total of 206 patients (serum creatinine [SCr] 1.3 ± 0.6 mg/dl, estimated glomerular filtration rate 55 ± 24 ml/min) who underwent PMVR were included. AKI was defined as an increase in SCr by ≥0.3 mg/dl within 48 hours or an increase in SCr by ≥1.5 times baseline. AKI was assessed during the first 5 days after MitraClip implantation. The incidence of AKI after MitraClip was 18% and none of the patients required dialysis. Age, logistic EuroSCORE, baseline renal function, N-terminal pro-B-type natriuretic peptide levels, serum glycated hemoglobin A1c, serum C-reactive protein, diuretic usage, and elevated right atrial pressure were the risk factors of AKI. Incidence of AKI was associated with poor outcome. Short-term mortality was increased (30-day mortality rate AKI vs no AKI: 18% vs 1%; p <0.001). Likewise, Kaplan-Meier analysis and log-rank test confirmed reduced long-term survival of patients with AKI (1-year all-cause mortality of patients with AKI vs patients with no AKI: 34% vs 13 %; p <0.001). In conclusion, every fifth patient experienced AKI after MitraClip implantation, which was associated with increased short-term mortality and a more than threefold increase in the risk of death 1 year after PMVR.

Citing Articles

Impact of diabetes mellitus on long-term survival after transcatheter mitral valve edge-to-edge repair.

Schmitt V, Geyer M, Born S, Bachmann K, Schnitzler K, Hell M Int J Cardiol Heart Vasc. 2025; 56:101601.

PMID: 39917728 PMC: 11800078. DOI: 10.1016/j.ijcha.2025.101601.


Frailty, periinterventional complications and outcome in patients undergoing percutaneous mitral and tricuspid valve repair.

Schafer M, Noth H, Metze C, Iliadis C, Korber M, Halbach M Clin Res Cardiol. 2024; .

PMID: 38358418 DOI: 10.1007/s00392-024-02397-3.


Comparison of costs associated with transcatheter mitral valve repair: PASCAL vs MitraClip in a real-world setting.

Haurand J, Haschemi J, Oehler D, Heinen Y, Polzin A, Kelm M BMC Health Serv Res. 2023; 23(1):945.

PMID: 37667270 PMC: 10476289. DOI: 10.1186/s12913-023-09966-8.


Anaesthesia for transcatheter mitral valve repair.

Dryden A, Hynes M, Hibbert B BJA Educ. 2023; 23(5):189-195.

PMID: 37124172 PMC: 10140472. DOI: 10.1016/j.bjae.2023.01.004.


Utility of frailty as a predictor of acute kidney injury in patients with aneurysmal subarachnoid hemorrhage.

Ng C, Dominguez J, Hosein-Woodley R, Feldstein E, Naftchi A, Lui A Interv Neuroradiol. 2022; 29(1):114-120.

PMID: 35109710 PMC: 9893237. DOI: 10.1177/15910199221076626.